Present status of BCG immunotherapy of malignant melanoma


BCG systemic adjuvant immunotherapy may be effective for improving both the recurrence and survival rates in patients with regional metastases from malignant melanoma. Clinical trials show that many of the principles derived from the study of animal tumor systems are applicable to human cancer in that immunotherapy is most effective for a small residual… (More)
DOI: 10.1007/BF00205300


5 Figures and Tables

Slides referencing similar topics